Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
Double-blind, Placebo-controlled Trial Investigating the Safety of Re-exposure to 900 mg of Org 34517, Used as Adjunctive Therapy in Subjects With Psychotic Major Depression (Major Depressive Episode, Severe, With Psychotic Features), Who Participated in Trial 28130
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Phase
Phase
- Phase 2
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- have attended Screening, Baseline, Visit Day 15, Day 29 and Day 43 of previous trial 28130;
- have a CGI of Severity score of 3 or greater at Day 43 of previous trial 28130 and at Day 1 of current trial 28133, or a lower score when the investigator is of the opinion that further resolution of symptoms is warranted;
- be on a stable dose of 'usual treatment', which must consist of an antidepressant, an antipsychotic, a mood stabilizer or any combination of these 3 drug classes.
Exclusion Criteria:
had experienced any of the following significant safety outcomes in previous trial 28130:
- severe breakthrough bleeding;
- diagnosis of prostatitis;
- abnormal level of testosterone at Day 15 of previous trial 28130;
- any adverse event deemed relevant for exclusion in trial 28133 by the investigator.
- had an abnormal PSA test at Day -7 of previous trial 28133
- were at significant risk of committing suicide, as indicated by a score greater than 9 on the revised ISST at Day -7 or Day 1;
- were currently treated with carbamazepine or valproate, midazolam, or clozapine;
- had been treated with electroconvulsive therapy (ECT) in the current episode;
- were currently treated with more than one antidepressant, antipsychotic, or mood stabilizer;
- had 'usual treatment' started or discontinued in the 2 weeks before Day 1;
- had a 'usual treatment' dose change within one week prior to Day 1;
- had any clinically unstable or uncontrollable renal, hepatic, respiratory, hematological, cardiovascular or cerebrovascular disease that would put the patient at risk of safety or bias assessment of efficacy;
- had known hypersensitivity reactions to glucocorticoid antagonists;
- had any clinically significant abnormal laboratory data (e.g. aspartate amino transferase (ASAT) and/or alanine amino transferase (ALAT) values > 2x normal range upper limit) or ECG results, or a clinically significant abnormal outcome at the physical examination at Day -7;
- had a confirmed positive result on the drug screening test for any illicit drug, except cannabis, at Day -7;
- had any untreated or uncompensated clinically significant endocrine disorder;
- were using hormone replacement therapy at Day -7;
- required concomitant treatment with corticosteroids (topical use was allowed);
- women of childbearing potential without adequate contraception
- women with a positive pregnancy test at Day -7 or 1, or are breast feeding mothers.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo
|
Placebo
|
|
Expérimental: Org 34517
Org 34517 titrated to 900 mg daily for 2 weeks
|
Org 34517 300 mg on Day 1, 600 mg on Day 2, then 900 mg daily starting from Day 3. Subjects in this arm were also to continue the "usual treatment" for psychotic major depression.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Safety and tolerability measures (vital signs, AEs)
Délai: 4 weeks
|
4 weeks
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
17-item Hamilton Rating Scale for Depression (HAMD) total score
Délai: 4 weeks
|
4 weeks
|
|
proportion of BPRS 30% responders; proportion of subjects with sustained BPRS 30% response
Délai: 4 weeks
|
4 weeks
|
|
proportion of HAMD 50% responders; proportion of subjects with sustained HAMD 50% response
Délai: 4 weeks
|
4 weeks
|
|
clinical global impression (CGI)
Délai: 4 weeks
|
4 weeks
|
|
PANNS total score
Délai: 4 weeks
|
4 weeks
|
|
PANSS positive scale score, PANSS negative scale score, PANSS general psychopathology score
Délai: 4 weeks
|
4 weeks
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- P05842
- EudraCT #: 2004-002156-34;
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .